PubMed Health⌕ Search

Biomedical subjects

E Wittmann

Publications and source records attributed to E Wittmann.

11 recordsLinked to original sources

Symptomatic hereditary type-II protein C deficiency caused by a missense mutation in exon IX of the protein C gene (Gly381 to Ser).

We report the characterization of the genetic defect in a family with hereditary type-II protein C (PC) deficiency. The propositus is a 28-year-old woman with a history of thrombosis. Her PC activity level (58%) and PC antigen level (115%) are compatible with the diagnosis of type-II PC deficiency. Her asymptomatic sister is also PC deficient. Analysis of the PC gene of the propositus revealed a point mutation (G to A) at nucleotide 8856, which results in the replacement of Gly381 by Ser in the heavy chain of PC. The amino acid change occurs close to the active-site serine at a residue which is highly conserved among the serine proteases. The mutation is also present in the PC gene of the propositus' sister. Her brother, who is asymptomatic, has a normal genotype with respect to the mutation at nucleotide 8856.

Adult↗

The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study.

BACKGROUND: Prospective studies on the incidence of thrombosis in asymptomatic individuals with hereditary protein C- or protein S deficiency have not been performed so far. OBJECTIVE: We have carried out a prospective cohort study in 44 asymptomatic protein C- and protein S deficient subjects and in 49 asymptomatic non-deficient relatives (age at study entry > 14 years) of symptomatic deficient patients. METHODS: 20 asymptomatic protein C deficient (median age 20 years) and 24 asymptomatic protein S deficient patients (median age 21.5 years) were prospectively followed and compared with 20 asymptomatic non-deficient relatives (median age 25 years) of protein C- and 29 (median age 27 years) of protein S deficient patients. The total observation period was 118.8 patient years for protein C deficient and 92.8 for protein S deficient patients. Patients were not on anticoagulants except for short duration in case of high risk situations. RESULTS: Eight thromboembolic events (1 pulmonary embolism, 1 deep vein thrombosis + pulmonary embolism, 3 deep vein thrombosis, 1 caval vein thrombosis and 2 superficial vein thrombosis) occurred in 6 deficient patients. The incidence of thromboembolism was 2.5% per patient year for protein C deficient and 3.5% per patient year for protein S deficient patients. 4 events occurred spontaneously, in 2 patients thromboembolic events were triggered by high risk situations (caesarean section, minor trauma). In the controls no thromboembolic events occurred. The probability for thromboembolism was significantly higher in protein C and protein S deficient patients compared to the control group (Wilcoxon test, p = 0.002, log rank test, p = 0.001). One major and 5 minor uneventful surgeries were carried out in the deficient patients using heparin prophylaxis. 1/8 pregnancies was complicated by superficial vein thrombosis during the second trimester despite prophylactic heparin administration. The same pregnancy was complicated by pulmonary embolism 5 weeks after delivery after discontinuation of heparin. CONCLUSIONS: Asymptomatic deficient relatives of symptomatic patients with protein C or protein S deficiency are at an increased risk of thrombosis compared to nondeficient individuals. Prophylactic treatment seems to be highly effective in high risk situations.

Adolescent↗

[Chronic lymphatic leukemia].

Chronic lymphocytic leukemia of the B-cell type (B-CLL) is the most common type of leukemia. The diagnosis is based on the demonstration of sustained lymphocytosis, bone marrow lymphocytosis and the presence of CD 19/CD5 positive cells. The most important prognostic factor is the stage of the disease (according to RAI or BINET) and the lymphocyte doubling time. Most early stage patients do not benefit from chemotherapy and, indeed, some of these patients never require treatment. Stage A patients with active disease and stage B patients are treated conventionally with chlorambucil/prednisone, but the optimum dosage and duration of chlorambcil treatment has not yet been established. In stage C patients anthracycline containing regimens appear to be more effective. The nucleoside analogues fludarabine and 2-chlorodeoxyadenosine (cladribine) have been shown to be active in patients refractory to alkylating agents. Their role in primary treatment is currently being evaluated in ongoing studies. For a small proportion of patients with advanced disease aged less than 55 years allogeneic or autologous bone marrow transplantation offers the chance of long term remission and possibly even cure, which never can be achieved with conventional chemotherapy.

Antineoplastic Combined Chemotherapy Protocols↗